A targeted drug called #repotrectinib received accelerated approval from the FDA for treating cancers linked to mutations called NTRK fusions. The clinical trial that resulted in the approval was co-led by thoracic oncologist Alexander Drilon MD. Learn more ⬇️ bit.ly/4c83bi0

Ashwin Shinde Matt Spraker C. Jillian Tsai, MD, PhD Nancy Lee We are uniform 30gy on ctv from around 2019ish — indeterminate nodes up to physician discretion — but if this is main thing preventing adoption, I think we can help spell it out more

Matt Spraker Mark Storey Eli Scher Nadeem Riaz C. Jillian Tsai, MD, PhD Sana Karam, MD, PhD Sean McBride Nancy Lee p16+ OPX consult today asked me own their own to specifically treat via the MSKCC approach Understands pros and possible limitations I’m very excited and hoping this will be first of many Nancy Lee Sean McBride C. Jillian Tsai, MD, PhD

BAD NEWS! -- Xevinapant +cis in HN Phase 3 negative at interim -- cis ineligible study closing down -- not great news for #hncsm #radonc NRG Oncology (h/t Yao Yu) C. Jillian Tsai, MD, PhD Sana Karam, MD, PhD Nancy Lee Henning Willers, MD emdgroup.com/en/news/xevina…

A very thoughtful opinion piece by Nancy Lee Memorial Sloan Kettering Radiation Oncology Lực Morris Max Diehn, MD/PhD outlining the caveats of using TTMV-HPV DNA as a routine biomarker for surveillance and treatment decision-making. Given the lack of robust sensitivity, such application should be carried out in

Must read for anyone considering incorporating NavDx into their routine practice for HPV-associated oropharynx cancers: jamanetwork.com/journals/jamao… Nancy Lee Max Diehn, MD/PhD Lực Morris Memorial Sloan Kettering Radiation Oncology

C. Jillian Tsai, MD, PhD Nancy Lee Memorial Sloan Kettering Radiation Oncology Lực Morris Max Diehn, MD/PhD Nadeem Riaz Sean McBride Yao Yu Scott Bratman Enrique Sanz-Garcia John De Almeida Christopher MKL Yao, MD. FRCSC David Sher Sana Karam, MD, PhD Excellent and thought provoking. Based on the work by David Routman , the view of Mayo Clinic Radiation Oncology has been that ctHPVDNA needs to be used to refine pathologic risk factors, rather than in lieu of pathologic risk factors for clinical trials, for reasons outlined here.

🧠⚡️🫁☢️New in Journal of Clinical Oncology from The Pike Lab Chad Rusthoven: The addition of up-front #radiation #SRS to CNS-penetrant #TKI ⬆️time-to-CNS progression & local control (but not OS) in pts with brain mets from #EGFR #ALK-driven #NSCLC #lungcancer. #lcsm #radonc ascopubs.org/doi/10.1200/JC…

☢️Learn about the Memorial Sloan Kettering Cancer Center #RadOnc Fellowships available at this OPEN HOUSE. 🧠CNS Fellowship led by Dr @Pike_Lab ⚡️Proton Fellowship led by Dr @IMRTLee ⚛️Brachytherapy Fellowship led by Dr @MarisaKollmeier 📅Monday, Sept 9 ⏲️8-9pm ET Register: meetmsk.zoom.us/meeting/regist…

Congrats Ethan Ludmir MD and Chad Tang, MD! This MD Anderson Cancer Center P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in #PancreasCancer pts with oligometastatic dz treated with metastasis-directed therapy+sys tx vs. sys tx alone. #radonc #endcancer ascopubs.org/doi/10.1200/JC…

This study is investigating the survival impact of aggressive local therapy in oligometastatic H&N cancer. Important question, and we need as many sites as possible. Please contact me if interested in opening in your center!

Nice to see our AFT-16 trial results published in JAMA Oncology. I think some of the best results seen in #radonc for Stage 3 NSCLC using a neoadjuvant & adjuvant ICB approach with chemoRT I like to call "peri-CRT" (ala "peri-operative"). Helen J. Ross, MD

🚀of Nancy Lee Nadeem Riaz Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center 🔮 30 Gy CCRT 🗣️#HNCSM #OPC #HPV total de-escalation U.S. FDA double-blind #radonc ph3 trial 2:1 arms 🔆FMISO selected (Hypoxia -ve 30 Gy, Hypoxia +ve 70 Gy gross/50 Gy subclin) ☢️SoC (70 Gy gross/50 Gy subclin) 🔋for 2y-OS

Our paper on a new approach to precision radiotherapy -- “Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy” led by Victor Ng and Sonali Sinha is out in Clinical Cancer Research #radonc #radbio (1/N) aacrjournals.org/clincancerres/…

With Nancy Lee and Ezra Rosen, we have initiated a Phase I/II trial (NCT05566574) to test this concept in humans with promising responses in first few patients enrolled (9/N)

1/n 🚨 🧬Our paper on the role of #mitochondria and free radicals in promoting the collapse of #Cancer #micronuclei is out in Science Magazine today. A story led by the brilliant Melody Di Bona it started with a simple question: why do micronuclei rupture? science.org/doi/10.1126/sc…

It is a BUSY fall season 🔥🔥🔥 A sure highlight is having Dr. Nadeem Riaz Nadeem Riaz give Mass General Cancer Center #radbio Grand Rounds this coming Tuesday‼️ Looking forward to hearing where #precision_radiation_medicine is heading 🙏 (ok that's a long hashtag😂)

🦊 Memorial Sloan Kettering Cancer Center scientists, including Drs. Goglia and Edward Christopher "Chris" Dee, MD, find an association between FOXA1 amplification and both enhanced metastatic potential and decreased survival, highlighting therapeutic potential in multiple cancer types. bit.ly/4gy1ddy

FMISO PET is often criticized for having low signal-to-noise. Great work from Rick Wray MD & Heiko Schoeder shows that training can increase inter-reader agreement from a kappa of 0.34 to 0.86! An important step to move FMISO from research to clinic. jnm.snmjournals.org/content/early/…

We are very grateful for Nadeem Riaz's Nadeem Riaz #RadBio MGH Grand Rounds lecture on "A Genetic and Microenvironmental Basis for Precision Radiotherapy" which is a🔥🔥topic‼️ Very inspiring, Nadeem!🙏 #Radiotherapy on the verge of becoming a *true* precision treatment❓🤔